Dr. Martin is internationally recognized for his groundbreaking discovery of microtentacles — thin, dynamic membrane protrusions found on the surface of breast cancer cells. These structures play a critical role in facilitating metastasis, the process by which cancer spreads to distant organs. This discovery has significantly deepened the oncology community’s understanding of tumor cell biology and opened new avenues for therapeutic intervention aimed at halting cancer dissemination at its earliest stages.

A hallmark of Dr. Martin’s recent work includes the invention of the TetherChip device, a novel microfluidic platform designed to preserve and analyze circulating tumor cells (CTCs) without disrupting vital structural features such as microtentacles. The TetherChip operates by preventing cell adhesion during sample processing, which historically compromised the integrity of these delicate structures. With a robust shelf life exceeding two years, this innovative device enables rapid and reliable testing of tumor biopsies, potentially allowing patients to receive diagnostic insights on the day of their biopsy procedure—a critical advancement toward personalized oncology.

Dr. Martin’s scientific inquiry focuses on the bioengineering and molecular characterization of tumor cell behaviors that underlie metastatic competence. His laboratory employs cutting-edge techniques that blend cellular biophysics, advanced imaging, and molecular pharmacology to delineate mechanisms that can be targeted pharmacologically. Supported by over $20 million in competitive funding from the National Cancer Institute, Department of Defense, and multiple cancer foundations, his research program is at the forefront of bridging fundamental science and clinical application.

In addition to his research accomplishments, Dr. Martin holds the prestigious Drs. Angela and Harry Brodie Professorship of Translational Cancer Research. This endowed position honors the legacy of Dr. Brodie, whose pioneering work on aromatase inhibitors dramatically transformed breast cancer therapeutics. Martin’s role as Deputy Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) further underscores his integral contribution to orchestrating multidisciplinary collaborative efforts aimed at advancing cancer treatment modalities.

A significant administrative achievement under Dr. Martin’s stewardship has been the successful merger of UMSOM’s Department of Pharmacology and Department of Physiology into a cohesive interdisciplinary unit. This consolidation harmonizes expertise across cancer therapeutics, molecular physiology, and neuropharmacology, fostering synergistic research initiatives. The unified department benefits from strategic partnerships with UMSOM’s various centers and institutes, as well as its proximity to the innovative BioPark property at 4MLK, a hub for biomedical entrepreneurship and translational research.

Dr. Martin’s prolific academic output includes over 90 peer-reviewed publications in distinguished journals such as Cancer Research, Proceedings of the National Academy of Sciences (PNAS), and Nature Communications. His work has accrued nearly 5,000 citations, reflecting the high impact and broad recognition of his contributions within the scientific community. His h-index of 42 is a testament to his sustained influence on the field of metastatic breast cancer biology.

His commitment to mentorship and education has been acknowledged with notable awards, including the Dr. Patricia K. Sokolove Outstanding Mentor Award and the GPILS Teacher of the Year Award, both highly valued recognitions from UMSOM graduate students. These accolades highlight Dr. Martin’s dedication to nurturing the next generation of scientists and fostering a collaborative research milieu conducive to intellectual growth and innovation.

Dr. Martin’s research trajectory illustrates a seamless integration of fundamental and translational sciences, from elucidating cellular mechanisms to developing clinical tools like the TetherChip. Efforts to obtain FDA approval for this device are ongoing and represent a promising step toward clinical implementation, potentially revolutionizing how metastatic potential is assessed in breast cancer patients. This innovation not only enhances diagnostic precision but also opens pathways for targeted therapies that intervene in metastatic processes.

In his role as Chair, Dr. Martin envisions an environment where scientific inquiry is driven by cross-disciplinary collaborations. He emphasizes the importance of integrating insights from physiology, pharmacology, and cancer biology to develop novel therapeutic interventions that address a broad spectrum of medical conditions. His leadership is anticipated to amplify UMSOM’s contributions to biomedical research and catalyze the translation of basic science discoveries into impactful clinical applications.

Dr. Martin’s early research training included a PhD in biomedical sciences from the University of California, San Diego, enriched by a Howard Hughes undergraduate research fellowship at the University of Virginia. He further honed his expertise during a Damon Runyon postdoctoral fellowship at Harvard Medical School, where he combined genomic studies with murine models of breast tumor metastasis under the mentorship of Dr. Phil Leder. This rigorous foundation laid the groundwork for his innovative approach to cancer metastasis research.

Beyond his research and administrative roles, Dr. Martin is actively engaged in the broader oncology community. He serves as Chair of the American Cancer Society Board for the Baltimore/DC Region and is a member of the American Association for Cancer Research. These affiliations underscore his commitment to advocacy, education, and fostering partnerships that support cancer research and patient care at multiple levels.

In summary, Stuart S. Martin, PhD, embodies the quintessential leader in translational cancer research, seamlessly blending scientific ingenuity with visionary departmental stewardship. His appointment as Chair of Pharmacology & Physiology at the University of Maryland School of Medicine promises to accelerate advances in the understanding and treatment of metastatic breast cancer, with transformative implications for patients worldwide.

Subject of Research: Breast cancer metastasis, tumor cell biology, drug development, pharmacology, physiology.

Article Title: Stuart S. Martin, PhD, Appointed Chair of Pharmacology & Physiology at University of Maryland School of Medicine

News Publication Date: 2024

Web References:
https://www.medschool.umaryland.edu/profiles/martin-stuart/
https://www.umms.org/umgccc
https://www.medschool.umaryland.edu/news/2020/um-school-of-medicine-researchers-develop-novel-test-for-microtentacles-on-breast-cancer-cells.html

Image Credits: University of Maryland School of Medicine

Keywords: Cancer research, Pharmacology, Physiology, Drug development, Cancer treatments, Neuropharmacology, Molecular physiology, Metastasis

Focused ultrasound, a technique that employs precisely targeted sound waves to influence biological tissues, stands at the intersection of physical science and biomedical engineering. Unlike conventional therapies, which often rely on systemic drug delivery or invasive surgical methods, focused ultrasound offers a non-invasive, highly localized approach capable of modulating tumor environments with unprecedented specificity. Dr. Sheybani’s research aims to harness this potential to boost the immune system’s ability to detect and destroy malignant breast cancer cells, potentially revolutionizing treatment paradigms.

Awarded the prestigious Breast Cancer Research Program Era of Hope Scholar Award, Dr. Sheybani is the first scholar from UVA to receive this honor, distinguishing her as a rising luminary in translational cancer research. This award supports early-career scientists with groundbreaking ideas poised to yield tangible clinical impact. Her project seeks not only to improve the safety profile of immunotherapeutic agents but also to increase their precision and therapeutic efficiency by utilizing ultrasonic waves as a highly controllable adjunct.

Immunotherapy, which has transformed oncology through immune checkpoint inhibitors and engineered cellular therapies, still faces significant challenges, particularly in solid tumors such as breast cancer. Tumor microenvironments often suppress immune cell infiltration or activation. Focused ultrasound offers a novel mechanism to modulate these biological barriers. Through mechanical energy delivered via sound waves, the technology can transiently disrupt the tumor stroma, enhance drug penetration, and stimulate local immune responses, effectively converting “cold” tumors into “hot” ones that are more receptive to immunotherapy.

Dr. Sheybani’s work uniquely integrates engineering principles with oncological science. As a faculty member in UVA’s Department of Biomedical Engineering—a joint program spanning the School of Medicine and the School of Engineering and Applied Science—her approach is inherently multidisciplinary. By calibrating acoustic parameters to optimize ultrasound-induced biological effects without causing tissue damage, her research addresses critical challenges in balancing treatment efficacy with patient safety.

Beyond the laboratory, Dr. Sheybani is spearheading efforts to bridge the divide between scientific discovery and patient experience. She intends to foster collaborative dialogues among clinicians, researchers, patients, caregivers, and advocates. This inclusive approach aims to enhance the relevance and impact of cancer research while fostering greater community engagement and understanding, which is crucial for accelerating the adoption of novel therapies and improving survivorship outcomes.

The era of personalized medicine demands technologies that offer flexibility and precision. Focused ultrasound epitomizes these qualities, providing dynamic control over treatment delivery while maintaining non-invasiveness. This allows for repeated or adjustable therapeutic sessions, tailored to individual patient needs. Such adaptability is particularly vital in oncology, where tumor heterogeneity and evolving resistance mechanisms often hamper standardized treatment regimens.

UVA has been a pioneering force in the development and clinical translation of focused ultrasound technology. Early work by Dr. Jeff Elias and colleagues established foundational applications in movement disorders such as essential tremor and Parkinson’s disease, earning FDA approval and setting the stage for expanded medical uses. In cancer treatment, the application of focused ultrasound is still emerging, but promising preclinical and clinical data suggest its transformative potential.

The establishment of the world’s first Focused Ultrasound Cancer Immunotherapy Center at UVA underscores the institution’s commitment to advancing this technology. This dedicated center amalgamates expertise across disciplines to develop combination strategies that harness ultrasonic modulation alongside immunotherapeutic drug delivery. Dr. Sheybani’s role as the inaugural research director reflects her exceptional qualifications and the innovative nature of her work.

Her research also delves into the biophysical interactions of ultrasound with immune cells and tumor tissues, investigating how acoustic energy influences cell signaling, vascular permeability, and immune cell trafficking. Understanding these mechanisms at the molecular and cellular levels is critical for refining treatment protocols and predicting patient response, ultimately aiming for precision-targeted cancer therapy with minimal off-target effects.

The Breast Cancer Research Program Era of Hope Scholar Award recognizes scientists who demonstrate extraordinary creativity, productivity, and vision in breast cancer research. According to Amy Bouton, PhD, professor emerita at UVA’s School of Medicine, Dr. Sheybani’s receipt of this award cements her position as a leading star in cancer research, simultaneously elevating UVA and its cancer center’s stature nationally and internationally.

At UVA Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in Virginia, this research synergizes with a broad spectrum of oncology programs focused on patient care, translational science, and community outreach. Integrating focused ultrasound into the clinical arsenal could accelerate the center’s mission to deliver cutting-edge, personalized therapies to cancer patients across the region and beyond.

Dr. Sheybani’s vision embodies a future where sound waves transcend their traditional roles in imaging and diagnostics, instead becoming potent therapeutic instruments that reshape tumor dynamics and empower the immune system. This paradigm shift has the potential to create therapies that are not only more efficacious but also safer and more patient-friendly, heralding a new chapter in non-invasive cancer treatment.

As this promising technology advances, it may also inspire the development of similar approaches across other cancer types and diseases characterized by challenging microenvironments. The project’s implications extend beyond breast cancer, offering a versatile platform for enhancing drug delivery and immune modulation in diverse clinical contexts.

With this substantial federal investment, Dr. Sheybani and her team have the resources to push the boundaries of focused ultrasound science, conducting rigorous preclinical studies, developing innovative instrumentation, and designing clinical trials that bring these innovations from bench to bedside. Their work stands as a beacon of hope for patients, offering the prospect of more effective, less toxic treatments forged at the nexus of engineering and medicine.

—

Subject of Research: Focused ultrasound technology to enhance cancer immunotherapy for breast cancer.

Article Title: Sound Waves Surge Ahead: Revolutionizing Breast Cancer Immunotherapy with Focused Ultrasound

Web References:

Focused Ultrasound Cancer Immunotherapy Center

https://uvahealth.com/services/focused-ultrasound

Homepage

Image Credits: UVA Health